Narrowing the gap: access to HIV treatments in developing countries. A pharmaceutical company's perspective
Narrowing the gap: access to HIV treatments in developing countries. A pharmaceutical company's perspective
复制标题
DOI：
10.1136/jme.26.1.47
复制
发表时间：
2000-02-01
影响因子：
4.1
通讯作者：
Cochrane, J
中科院分区：
文献类型：
--
作者：
Cochrane, J
新的抗逆转录病毒药物的出现意味着艾滋病毒的影响现在可以得到遏制，但到目前为止，只有二十分之一的感染者受益。对于那些生活在发展中国家的人来说，新的治疗方法实际上是无法实现的。各国政府、联合国艾滋病规划署和制药公司非常清楚地认识到这一点，并重新考虑了既定的假设，以便努力克服成本、保健服务不足和当地药品供应不可靠所带来的挑战。
The advent of new antiretroviral medicines means that the effects of HIV can now be curbed, but only one in twenty infected people have so far benefited. For those living in developing countries, the new treatments are practically unattainable. Governments, UNAIDS and pharmaceutical companies recognise this only too well and have rethought established assumption in order to try and overcome the challenges posed by cost, inadequate health services and unreliable local supply of medicines.